Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer

Mol Cancer Res. 2020 Feb;18(2):324-339. doi: 10.1158/1541-7786.MCR-19-0517. Epub 2019 Oct 31.

Abstract

The programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) pathway plays a pivotal role in the immune escape of tumors. Many tumor cells show "glutamine dependence." However, the relationship between glutamine metabolism and PD-L1 expression has not been reported. In this study, changes in PD-L1 expression in renal carcinoma cells were evaluated during glutamine deprivation and recovery. Although PD-L1 expression differed in two renal cancer cell lines, both cell lines upregulated PD-L1 during glutamine deprivation, and the upregulated PD-L1 was restored to normal after glutamine recovery. Mechanistically, glutamine deprivation resulted in activation of EGFR signaling via ERKs 1 and 2 (ERK1/2) and c-Jun. In addition, treatment of renal cancer cells with EGF also induced PD-L1 expression and ERK1/2 phosphorylation. Finally, inhibitors of EGFR, ERK, and c-Jun all inhibited phosphorylation of c-Jun and downregulated PD-L1 expression induced by glutamine deprivation. Taken together, the data suggest that glutamine regulates the expression of PD-L1 through the EGFR/ERK/c-Jun pathway in renal cancer. IMPLICATIONS: This study reveals glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun signaling in renal cancer and provides novel markers for the treatment of renal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / biosynthesis*
  • B7-H1 Antigen / metabolism
  • Cell Line, Tumor
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Gefitinib / pharmacology
  • Glutamine / deficiency*
  • Humans
  • Interferon-gamma / biosynthesis
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Kidney Neoplasms / metabolism*
  • Kidney Neoplasms / pathology
  • MAP Kinase Signaling System*
  • Neoplasm Staging
  • Protein Kinase Inhibitors / pharmacology
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / genetics
  • Signal Transduction
  • T-Lymphocytes / metabolism
  • Up-Regulation

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • Protein Kinase Inhibitors
  • RNA, Small Interfering
  • Glutamine
  • Interferon-gamma
  • EGFR protein, human
  • ErbB Receptors
  • JNK Mitogen-Activated Protein Kinases
  • Gefitinib